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ORIGINAL ARTICLE

Multi-Institutional Experience with FOLFIRINOX in
Pancreatic Adenocarcinoma
Parvin F Peddi1, Sam Lubner5, Robert McWilliams6, Benjamin R Tan1,
Joel Picus1, Steven M Sorscher1, Rama Suresh1, A Craig Lockhart1, Jian Wang7,
Christine Menias2, Feng Gao3, David Linehan4, Andrea Wang-Gillam1
1
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Louis, MO, USA. 5Division of Medical Oncology, Department of Medicine, University of
Wisconsin School of Medicine and Public Health. Madison, WI, USA. 6Division of Medical
Oncology, Mayo Clinic. Rochester, MN, USA. 7Division of Oncology, The Second Affiliated
Hospital of Zhengzhou University. Zhengzhou, Henan, China

ABSTRACT
Context Combination chemotherapy with FOLFIRINOX (oxaliplatin, irinotecan, fluorouracil, and leucovorin) was shown to be
effective in a large phase III trial. Objective The purpose of this study was to examine the tolerance and effectiveness of
FOLFIRINOX as practiced outside of the confines of a clinical trial and to document any dose modifications used by practicing
oncologists. Methods Data on patients with all stages of pancreatic adenocarcinoma treated with FOLFIRINOX at three institutions
was analyzed for efficacy, tolerance, and use of any dose modifications. Results Total of 61 patients was included in this review.
Median age was 58 years (range: 37 to 72 years), 33 were male (54.1%) and majority had ECOG performance of 0 or 1 (86.9%, 53
patients). Thirty-eight (62.3%) had metastatic disease, while 23 (37.7%) were treated for locally advanced or borderline resectable
disease. Patients were treated with a median number of four cycles of FOLFIRINOX, with dose modifications in 58.3% (176/302) of
all cycles. Ten patients had stable disease (16.4%), four had a partial response (6.6%) while eight had progressive disease (13.1%) on
best imaging following therapy. Median progression-free survival and overall survival were 7.5 months and 13.5 months,
respectively. The most common grade 3-4 adverse event was neutropenia at 19.7% (12 cases), with 4.9% (3 cases) rate of febrile
neutropenia. Twenty-one patients (34.4%) were hospitalized as a result of therapy but there were no therapy-related deaths. Twentythree (37.7%) had therapy eventually discontinued as a result of adverse events. Conclusion Despite substantial rates of adverse
events and use of dose modifications, FOLFIRINOX was found to be clinically effective in both metastatic and non-metastatic
patients. Regimen toxicity did not detract from overall response and survival.

INTRODUCTION

Received June 7th, 2012 - Accepted July 10th, 2012
Key
words
Adenocarcinoma;
Adult;
Antimetabolites,
Antineoplastic /adverse effects; Antineoplastic Combined
Chemotherapy Protocols /adverse effects; Follow-Up Studies;
Granulocyte Colony-Stimulating Factor; Neoadjuvant Therapy;
Pancreatic Neoplasms; Registries; Survival Analysis; United
States
Abbreviations ACCORD 11/PRODIGE 4: Action to Control
Cardiovascular Risk in Diabetes 11/Partenarait de Recherche en
Oncologie Digestive 4; ECOG: Eastern Cooperative Oncology
Group; FOLFIRINOX: oxaliplatin, irinotecan, fluorouracil, and
leucovorin; FOLFOX: oxaliplatin, fluorouracil, and leucovorin; GCSF: granulocyte colony stimulating factor
Correspondence Andrea Wang-Gillam
Division of Oncology; Campus Box 8056; Washington University
School of Medicine; 660 South Euclid Avenue; Saint Louis, MO
63110; USA
Phone: +1-314.362.5740; Fax: +1-314.362.7086
E-mail: awang@dom.wustl.edu

Pancreatic cancer remains the fourth leading cause of
cancer death in the U.S. with an estimated 37,390
deaths in 2012 [1]. Progress in combating this
malignancy has been slow with five year overall
survival improving from 3% in 1970s to merely 6% in
the early 2000s [1]. Until recently, the only
chemotherapy shown to provide a modest survival
benefit had been gemcitabine, which improved median
overall survival from 4.4 to 5.6 months when compared
to fluorouracil in a landmark phase III study [2].
Attempts at improving survival with combination of
gemcitabine and a variety of cytotoxic and molecularly
targeted agents have failed to provide substantial
additional benefit [3, 4, 5]. Addition of erlotinib to
gemcitabine was the only combination to provide a
modest additional survival benefit of 6% at 1 year,
resulting in an FDA approval for this agent [6].
In May 2011, Conroy et al. published the results of the
Action to Control Cardiovascular Risk in Diabetes 11 /
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Partenarait de Recherche en Oncologie Digestive 4
(ACCORD 11/PRODIGE 4) trial on FOLFIRINOX, as
the first regimen to improve the median overall
survival of patients with metastatic pancreatic cancer
beyond 10 months [7]. FOLFIRINOX, consisting of a
biweekly regimen of oxaliplatin, irinotecan,
fluorouracil, and leucovorin, was compared in a phase
II to III converted trial with gemcitabine in 342 patients
in various European centers. Median overall survival
was 11.1 months compared with 6.8 months in the
gemcitabine group. Furthermore, in spite of higher
rates of adverse events, patients in the FOLFIRINOX
group reported a higher quality of life.
In spite of the improvement in survival, however,
acceptance of FOLFIRINOX has been tempered with
toxicity concerns of this potent regimen. A similar
regimen (FOLFOXIRI: irinotecan 165 mg/m2 day 1
instead of 180 mg/m2 in FOLFIRINOX, same dose of
oxaliplatin at 85 mg/m2 day 1, leucovorin at 200 mg/m2
day 1, and fluorouracil at 3,200 mg/m2 48-hour
continuous infusion instead of 2,400 mg/m2 in
FOLFIRINOX) was tried in colon cancer and has not
been widely accepted partly due to similar toxicity
concerns [8]. We therefore sought to document the use
of FOLFIRINOX and its efficacy and tolerance in
patients treated at three U.S. academic institutions
within the framework of a registry study.
MATERIALS AND METHODS
Patient Population
Patients
with
pancreatic
adenocarcinoma
at
Washington University in St. Louis Siteman Cancer
Center, Mayo Clinic, and University of Wisconsin
Carbone Cancer Center, who were treated with
FOLFIRINOX between January 2009 and April 2012,
were eligible for inclusion. A retrospective and
prospective registry was established to capture all
patients after Institutional Board Review (IRB)
approval was obtained at each institution. Patients were
18 years of age or older and had pathologically
confirmed pancreatic adenocarcinoma. Treatment with
at least one cycle of a regimen consisting of 5fluorouracil, oxaliplatin, and irinotecan was required
for entry into the registry. Patients with all stages of
pancreatic cancer and prior treatment histories were
eligible. Demographic data collected included age,
race, gender, Eastern Cooperative Oncology Group
(ECOG) performance status, stage at initiation of
FOLFIRINOX, and any prior treatments. Baseline
laboratory values were recorded including tumor
marker CA 19-9. Data collection was stopped in March
2012.
Drug Administration
The standard FOLFIRINOX regimen has been
previously described in the ACCORD 11 trial [7],
consisting of oxaliplatin at 85 mg/m2, leucovorin at 400
mg/m2, irinotecan at 180 mg/m2, and fluorouracil at
400 mg/m2, followed by a continuous fluorouracil
intravenous infusion of 2,400 mg/m2 over a 46-hour

period every 2 weeks. Any deviation from this
regimen, whether in the first or subsequent cycles, was
recorded. The use of granulocyte colony stimulating
factor (G-CSF) support, given to prevent or decrease
levels of neutropenia, was recorded for each cycle.
Patients were followed until cessation of
FOLFIRINOX per the treating oncologist. The total
number of cycles received was recorded.
Evaluation of Clinical Toxicity
All clinic notes were reviewed for any hospitalizations,
dose reductions or cessation of treatment due to
adverse events. Laboratory values before and after each
treatment cycle were also reviewed to corroborate and
document any additional adverse events using
complete blood count and comprehensive metabolic
panel in each patient. Adverse events were graded
using National Cancer Institute Common Terminology
Criteria for Adverse Events (NCI CTCAE, version 3.0)
[9]. Most common adverse events specifically
tabulated in the paper include neutropenia, neutropenic
fever, thrombocytopenia, anemia, fatigue, nausea,
abdominal pain, and diarrhea. Patients who received at
least one cycle of chemotherapy were included for
toxicity evaluation.
Assessment of Clinical Benefit
Staging imaging (CT or MRI) was obtained per the
discretion of treating oncologists during treatment.
These images were analyzed according to the Response
Evaluation Criteria in Solid Tumors (RECIST) as
described in the supplement of the ACCORD trial to
determine response [7]. Images were included in
response analysis if patients had received at least three
cycles of a standard or modified FOLFIRINOX
regimen prior to image acquisition. Original report by
radiology was used for patients treated at Mayo Clinic
and University of Wisconsin. An independent
radiologist reviewed images of patients at Washington
University, for the purposes of this study. Best
response imaging was used for the purpose of
determining clinical benefit. Clinic notes were also
reviewed for clinician assessment of response and
when it differed from radiological assessment, the
clinical assessment of response was used.
ETHICS
Institutional Board Review (IRB) approval was
obtained at each institution. Written or oral informed
consent was obtained from each patient. The study
protocol conforms to the ethical guidelines of the
"World Medical Association (WMA) Declaration of
Helsinki - Ethical Principles for Medical Research
Involving Human Subjects" adopted by the 18th WMA
General Assembly, Helsinki, Finland, June 1964 and
amended by the 59th WMA General Assembly, Seoul,
South Korea, October 2008.
STATISTICS
Data analysis for this study was descriptive in nature.
Demographic and clinical characteristics, as well as
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Table 1. Characteristics of 61 patients with pancreatic
adenocarcinoma treated with FOLFIRINOX between January 2009
and April 2012.
Institution:
- Washington University
- Mayo Clinic
- University of Wisconsin
Age (year):
- Median
- Range

31 (50.8%)
12 (19.7%)
18 (29.5%)
58
37-72

Gender:
- Male
- Female

33 (54.1%)
28 (45.9%)

Ethnicity:
- White
- African Americans

56 (91.8%)
5 (8.2%)

ECOG performance status:
- 0-1
- 2 or unknown

53 (86.9%)
8 (13.1%)

Tumor location:
- Head
- Other locations or resected

25 (41.0%)
36 (59.0%)

Biliary stent

17 (27.9%)

Stage:
- Metastatic
- Locally advanced
- Borderline resectable

38 (62.3%)
19 (31.1%)
4 (6.6%)

adverse events and follow-up time were summarized
using means, medians, and standard deviations, ranges
or counts and frequencies as appropriate. Progressionfree survival was defined as time of FOLFIRINOX
initiation to time of progression based on
imaging/clinical evaluation, or time of death,
whichever occurred first. Those patients alive and
progression-free were censored on March 1st, 2012, the
date of data collection close. Overall survival was
defined as time of FOLFIRINOX initiation to time of
death. When not noted in clinical records, the Social
Security Death index was used to ascertain survival
and patients alive were censored in March 2012. The
overall and progression-free survival were calculated
using Kaplan-Meier product limit methods. Statistical
analyses were performed using SAS (SAS Institutes,
Cary, NC, USA).
RESULTS
Patients
Patient characteristics are shown in Table 1. A total of
61 patients were enrolled and followed for a median of
8.5 months (range of 1.5 to 20.4 months). Median age
was 58 with a range of 37 to 72 years. Majority of the
patients were male (54.1%), white (91.8%) and with
ECOG performance of 0 or 1 (86.9%). Thirty-eight
(62.3%) patients were treated for metastatic or
recurrent disease, while 19 (31.1%) had locally
advanced cancer and 4 had border-line resectable
disease (6.6%). Twenty-five patients (41.0%) had
tumor present in the pancreatic head at time of
receiving FOLFIRINOX with 17 patients (27.9%)
having a biliary stent.

Treatment
Patients received a median of 4 cycles of
FOLFIRINOX with range of 1 to 22 cycles. Average
number of cycles was 5.4. Three patients started with
one cycle of FOLFOX (same dosage and schedule of
oxaliplatin, 5-FU, and leucovorin as FOLFIRINOX,
but omitting irinotecan) to test tolerability before the
addition of irinotecan. This first cycle of FOLFOX was
not counted towards cycle count or analysis.
The FOLFIRINOX regimen was modified in 31
patients (50.8%) empirically starting with the first
cycle. Deletion of 5-FU and dose reduction of
irinotecan were the most common modifications and
were each selected for 22 patients with some overlap of
the two groups. Thirty-two patients had UTG1A1
status evaluated and dose reduction of irinotecan was
done in 4 patients due to presence of UGT1A1*28/28
genotype. Median dose intensities for the first cycle for
each of the components were 100%. Average dose
intensities for the first cycle for oxaliplatin, irinotecan,
5-FU bolus, and 5-FU continuous infusion were 98%,
90%, 59%, 99%, respectively. Overall dose averages
for oxaliplatin, irinotecan, 5-FU bolus, and 5-FU
continuous infusion were 96%, 88%, 57%, and 96%,
respectively. From the 31 patients who started with full
dose FOLFIRINOX, 20 (64.5%) required eventual
dose reduction or discontinuation of therapy due to
adverse events.
G-CSF support was included for 41 patients (67.2%)
starting with the first cycle using filgastrim. Except for
three patients in whom G-CSF support was later
discontinued, all others were continued on G-CSF for
all subsequent cycles. On the other hand, from the
twenty patients who were not started on G-CSF with
first cycle, 6 (30.0%) had G-CSF support added later
on. Overall 47 patients (77.0%) received G-CSF
support at some point in their therapy.
Adverse Events
There were no deaths as a result of therapy. In six
patients (9.8%) treatment was stopped after the first
cycle due to adverse events. Rates of the most common
grade 3-4 adverse events are listed in Table 2.
Neutropenia was the most common grade 3-4 adverse
event, occurring in 12 patients (19.7%), while
neutropenic fever occurred in three patients (4.9%).
Table 2. Severe adverse events observed in 61 patients with
pancreatic adenocarcinoma treated with FOLFIRINOX.
Hematologic:
- Neutropenia
- Febrile neutropenia
- Thrombocytopenia

12 (19.7%)
3 (4.9%)
2 (3.3%)

Non-hematologic:
- Abdominal pain
- Fatigue
- Diarrhea

5 (8.2%)
3 (4.9%)
2 (3.3%)

Other grade 3-4 adverse events

7 (11.5%)

Hospitalization

21 (34.4%)
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Table 3. Reason for discontinuation of therapy reported by 61
patients with pancreatic adenocarcinoma treated with FOLFIRINOX.
Adverse events

23 (37.7%)

Disease progression

18 (29.5%)

Resection

8 (13.1%)

Other reasons/Ongoing

12 (19.7%)

Two of these patients were already on G-CSF
prophylaxis but were on full dose FOLFIRINOX
therapy. Grade 3 or worse thrombocytopenia occurred
in two patients (3.3%) while no patient had a grade 3-4
anemia. Abdominal pain, fatigue and diarrhea were the
severe non-hematological adverse events that were
observed. Intravenous fluids and anti-diarrhea
medications as outpatient usually sufficed for treatment
but hospitalizations were required for a total of 21
patients (34.4%). There was one case of cholangitis
whose tumor was in the pancreatic head and did not
have a stent. No definite correlation was observed
between adverse events and UGT1A1 genotype.
Adverse events caused dose reduction in 23 patients
(37.7%) and resulted in the eventual reason for
discontinuation of FOLFIRINOX in 23 patients
(37.7%). Overall eleven patients (18.0%) received full
dose FOFIRINOX throughout their treatment without
adverse events necessitating dose reduction or
cessation. Reason for eventual discontinuation of
FOLFIRINOX therapy is depicted in Table 3.
Clinical Outcome
Forty patients (65.6%) had imaging available after at
least three cycles of FOLFIRINOX therapy: 22 with
metastatic disease (57.9%) and 18 with non-metastatic
disease (78.3%). Overall, one patient had complete
response (2.5%), nine patients had a partial response
(22.5%), 19 had stable disease (47.5%), and 11 had
disease progression (27.5%) (Table 4). All four patients
with borderline resectable disease receiving
FOLFIRINOX were able to undergo resection
afterwards. From the 19 patients with locally advanced
disease, 4 (21.1%) were also able to undergo resection
after receiving radiation following FOLFIRINOX
therapy. From the 18 patients with non-metastatic
disease who had imaging available, 9 (50.0%) had
stable disease, 5 (27.8%) partial response and 1 (5.6%)
had a complete response post treatment with
FOLFIRINOX. From the 22 patients with metastatic
disease, 14 (63.5%) had either partial response or
stable disease.

A total of 23 patients died (37.7%) and 29 patients
progressed (47.5%). Median progression-free survival
was 7.5 months, with 1-year progression-free survival
of 35.3%. Overall survival was recorded using medical
records and Social Security Death index for all
patients. Median overall survival was 13.5 months,
with 1-year overall survival of 55.6% (Figure 1). Oneyear overall survival for patients with metastatic
disease was 41.8% compared with 75.5% without
metastasis.
DISCUSSION
This is the first study to our knowledge examining
FOLFIRINOX use outside of a clinical trial after the
ACCORD study in U.S. patients with pancreatic
adenocarcinoma [10]. FOLFIRINOX was found to be
widely adopted at the centers examined in this study,
not only in patients with metastatic disease who were
the patient population studied in the ACCORD trial,
but also in locally advanced and borderline-resectable
disease.
Given concerns for toxicities, FOLFIRINOX dosage
was frequently adjusted empirically as well as in
response to adverse events. In fact half of the patients
were given reduced dosing of FOLFIRINOX starting
with the first cycle before the development of any
adverse events. Nonetheless, a significant portion of
the patients (34.4%) were hospitalized due to adverse
events. The rate of hospitalizations was not reported in
the ACCORD trial. Only one case of cholangitis was
seen, which is reassuring given the high propensity of
stents in this patient population. A higher proportion of
patients received G-CSF compared to the ACCORD
trial (77.0% vs. 42.5%). Accordingly, rates of grade 3-4
neutropenia were lower in our patient population
(19.7% vs. 45.7%) but rates of neutropenic fever were
similar in both studies at less than 5%.
In spite of dose reductions, FOLFIRINOX was found
to be very effective. Rates of response were similar to

Table 4. Best response observed in 40 patients with pancreatic
adenocarcinoma with imaging available after at least three cycles of
FOLFIRINOX. Results are stratified according to the presence of
metastatic disease.
Non-metastatic
Metastatic disease
(n=22)
disease (n=18)
0

1 (5.6%)

Partial response

4 (18.2%)

5 (27.8%)

Stable disease

10 (45.5%)

9 (50.0%)

Progressive disease

8 (36.4%)

3 (16.7%)

Complete response

Figure 1. a. Overall survival in all patients and subset with
metastatic disease. b. Progression-free survival for the same patients.
(The number of cases exposed to risk are also reported).

JOP. Journal of the Pancreas - http://www.serena.unina.it/index.php/jop - Vol. 13 No. 5 - September 2012. [ISSN 1590-8577]

500

JOP. J Pancreas (Online) 2012 Sep 10; 13(5):497-501.

the ACCORD study with more than 70% of patients
having at least stable disease on therapy. Similar
response rates were seen in non-metastatic patients
who were not included in the ACCORD trial. In fact, 8
patients were able to undergo resection after
FOLFIRINOX therapy. This is notable given the
extensive desmoplastic stroma reaction in localized
disease and concern for reduced efficacy of
chemotherapy in this setting. Progression-free and
overall survivals were longer than the results published
in the ACCORD trial (7.5 months and 13.5 months,
respectively) likely reflecting inclusion of patients with
non-metastatic disease. One-year survival rate for
patients with metastatic disease was 41.8%, similar to
the 48.4% reported in the ACCORD trial.
The strength of this study is that it provides real world
data on the use of FOLFIRINOX in patients with
pancreatic cancer. Moreover, it provides the first data
on patients treated in the U.S.. In addition, it includes
patients with non-metastatic disease that were not
included in the original ACCORD trial. The use of
FOLFIRINOX in these patients has been reported in at
least one other retrospective study and is promising
[11]. One weakness of this study is that dose reductions
were not protocol driven and instead were up to the
discretion of the treating oncologists. As a result, it is
difficult to judge if all treatment modifications were
performed in a standard fashion or were clinically
necessary. Similarly, not all physicians obtained tumor
markers at regular intervals and therefore our study did
not attempt to correlate tumor marker levels with
response. Another weakness of this study is that the
median age of patients at 58, while similar to the
ACCORD study, was much younger than median age
of 71 observed in the SEER database [12]. It is
therefore important to note that it is not known whether
older patients would tolerate this regimen. In regards to
the use of G-CSF, rates of febrile neutropenia seen in
this study do not justify use of growth factors per
NCCN guidelines. However, given that 77.0% of
patients received growth factor support, it could be
argued that the rates of febrile neutropenia were low
only as a result. It may therefore be reasonable to
include G-CSF support with this regimen and later
discontinue it if not needed.
In conclusion, we believe it is acceptable to use
FOLFIRINOX instead of gemcitabine monotherapy in
future clinical trials as the new gold standard in
patients with pancreatic cancer given its efficacy and
acceptable rate of adverse events. It remains to be seen
how FOLFIRINOX compares to other regimens
currently in clinical trials, such as combination of
gemcitabine with nab-paclitaxel, which has had
promising results in phase I/II trials [13]. It is also not
known whether FOLFIRINOX can serve as a backbone
chemotherapy to which targeted agents, such as
erlotinib, could be added similarly to what had been
done with gemcitabine. Increased toxicity may
preclude addition of other agents to FOLFIRINOX.

Use of UTG1A1 testing and appropriate irinotecan
dose reduction may be useful in reducing at least some
of the toxicities. At the present time, however,
FOLFIRINOX by itself is more effective than any
other regimen in patients with pancreatic cancer and its
toxicities did not preclude its use in the patients studied
in this review.
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